Abstract
Regorafenib is a tyrosine kinase domain inhibitor in a number of receptors, and so far it has been used to treat metastatic colorectal cancer. Based on the results of the GRID study, it is indicated for the treatment of patients with advanced gastrointestinal stromal tumour as well who progressed on imatinib or sunitinib.